Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Total Non-Current Liabilities (2018 - 2025)

AVITA Medical's Total Non-Current Liabilities history spans 8 years, with the latest figure at $71.8 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities changed 0.37% year-over-year to $71.8 million; the TTM value through Dec 2025 reached $71.8 million, changed 0.37%, while the annual FY2025 figure was $71.8 million, 0.37% changed from the prior year.
  • Total Non-Current Liabilities reached $71.8 million in Q4 2025 per RCEL's latest filing, up from $68.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $71.8 million in Q4 2025 to a low of $8.1 million in Q1 2022.
  • Average Total Non-Current Liabilities over 5 years is $41.6 million, with a median of $59.3 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: dropped 11.18% in 2022, then surged 405.49% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $11.3 million in 2021, then grew by 3.02% to $11.6 million in 2022, then soared by 405.49% to $58.7 million in 2023, then increased by 21.8% to $71.5 million in 2024, then rose by 0.37% to $71.8 million in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Total Non-Current Liabilities are $71.8 million (Q4 2025), $68.5 million (Q3 2025), and $69.1 million (Q2 2025).